12:00 AM
 | 
Sep 29, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Enbrel etanercept: Pivotal trial data

In the open-label CRYSTEL trial in 720 patients who had failed or could not use standard therapies, Enbrel improved measures of psoriasis severity and measures of joint pain, depression and anxiety, and quality of life. Patients received 25 mg twice-weekly injections for 54 weeks (n=357) or 50 mg twice-weekly injections until response and then continuing at relapse (n=363, "paused group"). In 711 evaluable patients, mean PGA scores improved by 47% in the continuous group and 43% in the paused group at week...

Read the full 388 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >